Medicaid expansion and racial disparity in timely multidisciplinary treatment in muscle invasive bladder cancer
JNCI: Journal of the National Cancer Institute · 2023
DOI: 10.1093/jnci/djad112 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2023. Verfasst von Changchuan Jiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Hauptthemen laut MEDLINE: Medicaid, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Background
Multidisciplinary cancer care (neoadjuvant chemotherapy followed by radical cystectomy or trimodality therapy) is crucial for outcome of muscle-invasive bladder cancer (MIBC), a potentially curable illness. Medicaid expansion through Affordable Care Act (ACA) increased insurance coverage especially among patients of racial minorities. This study aims to investigate the association between Medicaid expansion and racial disparity in timely treatment in MIBC.
Methods
This quasi-experimental study analyzed Black and White individuals aged 18-64 years with stage II and III bladder cancer treated with neoadjuvant chemotherapy followed by radical cystectomy or trimodality therapy from National Cancer Database 2008-2018. Primary outcome was timely treatment started within 45 days following cancer diagnosis. Racial disparity is the percentage-point difference between Black and White patients. Patients in expansion and nonexpansion states were compared using difference-in-differences and difference-in-difference-in-differences analyses, controlling for age, sex, area-level income, clinical stage, comorbidity, metropolitan status, treatment type, and year of diagnosis.
Results
The study included 4991 (92.3% White, n = 4605; 7.7% Black, n = 386) patients. Percentage of Black patients who received timely care increased following the ACA in Medicaid expansion states (54.5% pre-ACA vs 57.4% post-ACA) but decreased in nonexpansion states (69.9% pre-ACA vs 53.7% post-ACA). After adjusting covariates, Medicaid expansion was associated with a net 13.7 percentage-point reduction of Black–White patient disparity in timely receipt of MIBC treatment (95% confidence interval = 0.5% to 26.8%; P < .01).
Conclusions
Medicaid expansion was associated with statically significant reduction in racial disparity between Black and White patients in timely multidisciplinary treatment for MIBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
- Department of Medicine, Peking Union Medical College, Beijing, China.
- Surveillance and Health Equity Science, American Cancer Society, Atlanta, GA, USA.
ORCID-Profile: Changchuan Jiang, Lei Deng, Xuesong Han, Dharmesh Gopalakrishnan
Förderung
- AstraZeneca
Zitieren
APA
Jiang, C., Perimbeti, S., Deng, L., Xing, J., Chatta, G. S., Han, X., & Gopalakrishnan, D. (2023). Medicaid expansion and racial disparity in timely multidisciplinary treatment in muscle invasive bladder cancer. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djad112
Vancouver
Jiang C, Perimbeti S, Deng L, Xing J, Chatta GS, Han X, et al. Medicaid expansion and racial disparity in timely multidisciplinary treatment in muscle invasive bladder cancer. JNCI: Journal of the National Cancer Institute. 2023. doi:10.1093/jnci/djad112
BibTeX
@article{Jiang2023,
author = {Jiang, Changchuan and Perimbeti, Stuthi and Deng, Lei and Xing, Jiazhang and Chatta, Gurkamal S and Han, Xuesong and Gopalakrishnan, Dharmesh},
title = {Medicaid expansion and racial disparity in timely multidisciplinary treatment in muscle invasive bladder cancer},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2023},
doi = {10.1093/jnci/djad112}
}
EUVIMED